Enabling Insight-Based
Decision Making
radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organisation, optimising the development of new oncology treatments.
Who We are
radiomics.bio is a medical imaging research organisation.


pioneer in the field of radiomics
radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organisation, optimising the development of new oncology treatments. radiomics.bio supports biotech and pharma companies in all stages of clinical development. radiomics.bio provides quantification of treatment response, exploration and validation of drug mechanisms of action, and develops predictive tools for insight-based decision making.
Advanced Image Management
Our Ikonics® platform, is a fully integrated image management that streamlines image collection and centralises image quality assessment for enhanced efficiency
We ensure enhanced efficiency through our fully integrated platform, Ikonics®. Our in-house platform allows us to streamline our workflow and allows for a robust analysis process.

radiomics.bio enables insight-based decision making to optimise clinical trials and drug development studies
From image acquisition to regulatory reporting in all stages of clinical research.
Characterise disease using volumetric and radiomic imaging features to enhance understanding of disease on a patient, organ, or lesion level leading to insightful and cost-effective clinical trial designs.

Evaluate therapeutic efficiency to quantify treatment response (per arm, per dose, per indication, etc.) to facilitate objective decisions based on drug success potential for each phase of clinical development.

Characterise biological response to explore and validate the mechanisms of actions of your drug.

Predict clinical outcome using imaging and clinical data to obtain early insights during clinical trials for decision-making.


Optimise your medical image management; radiomics.bio supports the development of imaging protocols, collects and stores your images in compliance with regulatory and privacy requirements for future use, and conducts standard analysis of oncological images such as RECIST suite assessment to analyse treatment efficacy

What’s new at radiomics.bio?

radiomics.bio Announces New Chairman

Paul Mauhin appointed Chief Financial Officer of radiomics.bio, succeeding Mathieu Delvaux

From Images to Impact: Radiomics’ Solutions to Challenges in Immunotherapy
